Bath & Body Works (NYSE:BBWI) Issues FY26 Earnings Guidance

Bath & Body Works (NYSE:BBWI) issued an update on its FY26 earnings guidance on Tuesday morning. The company provided EPS guidance of $3.25-360 for the period, compared to the consensus EPS estimate of $3.61. Bath & Body Works also updated its Q1 guidance to $0.36-0.43 EPS.

Bath & Body Works Trading Down 1.7 %

Bath & Body Works stock opened at $29.29 on Thursday. The company has a market capitalization of $6.34 billion, a price-to-earnings ratio of 7.14, a price-to-earnings-growth ratio of 0.92 and a beta of 1.89. Bath & Body Works has a 12 month low of $26.20 and a 12 month high of $52.99. The business’s fifty day simple moving average is $36.72 and its two-hundred day simple moving average is $34.07.

Bath & Body Works (NYSE:BBWI) last announced its quarterly earnings results on Thursday, February 27th. The company reported $2.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.05. The firm had revenue of $2.79 billion for the quarter, compared to the consensus estimate of $2.78 billion. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. On average, equities research analysts predict that Bath & Body Works will post 3.3 EPS for the current year.

Bath & Body Works Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, February 21st were given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date was Friday, February 21st. Bath & Body Works’s dividend payout ratio (DPR) is presently 21.98%.

Bath & Body Works announced that its board has approved a share repurchase plan on Thursday, February 27th that permits the company to buyback $500.00 million in shares. This buyback authorization permits the company to reacquire up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board believes its shares are undervalued.

Analyst Upgrades and Downgrades

BBWI has been the subject of a number of research reports. Barclays reduced their price objective on Bath & Body Works from $43.00 to $38.00 and set an “equal weight” rating for the company in a research report on Monday, March 3rd. JPMorgan Chase & Co. set a $47.00 price objective on shares of Bath & Body Works in a research report on Thursday, February 27th. Deutsche Bank Aktiengesellschaft upped their price objective on Bath & Body Works from $51.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, November 26th. Telsey Advisory Group reiterated an “outperform” rating and set a $43.00 target price on shares of Bath & Body Works in a research report on Thursday, February 27th. Finally, Piper Sandler upped their price target on Bath & Body Works from $36.00 to $39.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $45.06.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America’s Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.